Explore the AgendaFrom causal biology to blowing up the small molecule paradigm, join the discussion at Grand Rounds

SPEAKERS

Learn from 50+ industry thought leaders, including:

Kristen Hege, M.D.
Board Member, Adaptimmune, Mersana, Kelonia and former SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy
Bristol Myers Squibb
John Lepore, M.D.
CEO
ProFound Therapeutics
Deborah Palestrant, Ph.D.
Exec. Chair, 4:59 Initiative & Partner
5AM Ventures
Mathai Mammen, M.D., Ph.D.
Chairman & CEO
FogPharma
Gregory Verdine, Ph.D.
Co-Founder, President & CEO, LifeMine Therapeutics, and Professor of Chemistry
Harvard University
Erin Kimbrel, Ph.D.
President & Head of Astellas Institute for Regenerative Medicine
Astellas
View Moreright-arrow
Presenting Company Dashboard:Research Pipelines, Financings, Deals
Sponsorship Opportunities:Highlight Your Thought Leadership

Grand Rounds 2024

BioCentury's 1st R&D conference: At the Academia/Industry Interface

Join BioCentury, biotech decision-makers and the next innovators in Nashville Sept. 9-11, 2024.

Event Details

At BioCentury Grand Rounds, discover the next wave of biotech breakthroughs and the people driving them. Be part of the dialogue solving today’s problems in translation to enable tomorrow’s medicines.

Why Attend?

Shape the next generation of treatments: Find opportunities in groundbreaking research to build your portfolios and pipelines; meet the investors and partners who can convert your discoveries to programs and launch new companies

Connect with Industry Leaders:

Participate in panels and fireside chats with key thought leaders to explore critical translation issues and gain valuable perspectives.

Expand Your Network:

Build invaluable connections through 1:1 partnering and networking sessions, fostering collaboration with VCs, pharmas, biotechs and fellow innovators.

BioCentury’s inaugural R&D conference presents a pivotal meeting point for academic innovators, physician scientists, and industry leaders. This first-of-its-kind conference zeroes in on the academia/industry interface, spotlighting the earliest stages of discovery with significant commercial potential, fostering the conversion of groundbreaking science into impactful drug development programs, and addressing the critical bottlenecks in translational medicine.

The conference will feature:

  • Poster presentations by academic innovators
  • Poster and oral presentations by presenting companies
  • Fireside chats with key thought leaders in industry and academia
  • Panel discussions on critical topics for the translation of scientific discoveries into drug development programs
  • 1:1 partnering
  • Networking

Download the conference brochureFor more information on who you will meet, the full agenda, and more.

Grand Rounds 2024 Preview

Steering Committee

Amy Abernethy, M.D., Ph.D.
Former Principal Deputy Commissioner
FDA
Chris Arendt, Ph.D.
CSO, Head of Research
Takeda
Jane Grogan, Ph.D.
EVP, Head of Research
Biogen
Fiona Marshall, Ph.D.
President of Biomedical Research
Novartis
Robert Plenge, M.D., Ph.D.
EVP, Chief Research Officer
Bristol Myers Squibb
Cary Pfeffer, M.D.
Partner
Third Rock Ventures
View Moreright-arrow

Sponsors

Interested in becoming a Presenting Company for the first annual Grand Rounds in Nashville?Apply now to be considered for the Grand Rounds Class of 2024